How much revenue does Granules India make?

Granules India reported 44.56 billion INR in revenue for fiscal year 2025, down 0.8% from 44.90 billion INR in fiscal year 2024. In Q2 2026 revenue was 12.95 billion INR.

Where does Granules India make most of its revenue?

Outside India: 94% of revenue by region in fiscal year 2025, followed by India (6%).

What companies are similar to Granules India?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS), Emcure Pharmaceuticals L (EMCURE.NS), Wockhardt Limited (WOCKPHARMA.NS), Caplin Point Laboratories Limited (CAPLIPOINT.NS).

Granules India Limited (GRANULES.NS) Stock

About Granules India Limited

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsule...

At a glance

Granules India reported revenue of 44.56 billion INR for fiscal year 2025, down 0.8% from fiscal year 2024, and net income of 5.02 billion INR. In Q2 2026 (the quarter ended September 30, 2025) revenue was 12.95 billion INR, up 35.4% from a year before. Outside India was its largest region in fiscal year 2025, with 94% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.